Freenome

Freenome is a biotechnology company founded in 2014 and headquartered in Brisbane, California. It develops a multiomics blood-based platform for the early detection of cancer, combining genomics, proteomics, and epigenetics with machine learning to identify cancer signals from a standard blood draw. The company's technical work spans assay development, bioinformatics, clinical research, and AI model development, with a stated focus on iterating machine-learning models alongside laboratory process optimisation and clinical trial design.

The company operates as an interdisciplinary organisation in which molecular biologists work alongside machine-learning engineers, data scientists, and clinicians. Scientists and engineers partner on the design of scalable assays, and cross-functional teams address scientific problems across the full pipeline from wet lab to model to clinic. Work is organised around hands-on, iterative development rather than isolated functions.

Freenome has raised more than $1.3 billion in total capital and maintains strategic partnerships with Roche, Exact Sciences, and Siemens Healthineers. Its work sits at the intersection of healthcare, cancer screening, diagnostics, genomics, and clinical research.

The company reports a mission-driven culture oriented around early detection of cancer. As part of a commitment to health equity and accessibility, it has partnered with Morehouse School of Medicine to help ensure clinical studies represent all populations.